HIMS · Hims & Hers Health, Inc. · Stock research

Current Thesis

The binary that framed the prior note resolved on 2026-08-10, and it split. Revenue came in at $753.2M, up 38% from $544.8M in Q2 2025 — above the company's own $680–700M band and above the $699.9M consensus. Q3 was guided to $880–900M against a $793.1M street estimate, and FY2026 revenue was raised to $3.1–3.3B from $2.8–3.0B. The reacceleration that was a guidance promise in May is now a reported number. The other half of the print went the other way: gross margin 64% versus 76% a year earlier, a GAAP net loss of $86.3M against $42.5M of net income in Q2 2025, EPS of −$0.37 versus a −$0.03 consensus, and an FY adjusted-EBITDA band trimmed at the top to $275–325M from $275–350M. Shares fell on 2026-08-10 and 2026-08-11 on the mixed print, then recovered to a 2026-08-21 close of $33.78 — above the $31.59 pre-print reference close of 2026-08-07, and still 46.2% under the 52-week high of $62.76. The narrative leg on offer now is that a 38%-growth, $3.1–3.3B-revenue subscription platform is being valued as if the margin reset is permanent.

Bullish and bearish views on Hims & Hers Health, Inc.

The model's bull view on Hims & Hers Health, Inc. (HIMS), in brief: Revenue reacceleration is measured, not guided: $753.2M in Q2 2026, +38% YoY, clearing the $700M top of the company's guide and the $699.9M consensus (2026-08-10 release). The bear view: The margin reset is the actual event: 64% gross margin versus 76% in Q2 2025, and a swing to an $86.3M net loss from $42.5M of net income. Both cases follow in full.

Bull Case

• Revenue reacceleration is measured, not guided: $753.2M in Q2 2026, +38% YoY, clearing the $700M top of the company's guide and the $699.9M consensus (2026-08-10 release).
• The forward guide moved more than the quarter did: Q3 2026 revenue $880–900M against a $793.1M consensus, and FY2026 lifted roughly $300M at the midpoint to $3.1–3.3B (2026-08-10).
• Mix is carrying price, not only volume: subscribers 2.891M, +19% YoY, while monthly revenue per average subscriber reached $92, +21% YoY (Q2 2026 release).
• Still EBITDA-positive through the transition: adjusted EBITDA $60.3M in Q2 2026, struck after $28.5M of first-half restructuring charges tied to the shift from compounded to branded GLP-1s.
• Balance sheet funds the build: cash and equivalents $609.8M at 2026-06-30.
• Post-print revisions skewed higher: Needham to $42, BofA $30→$32, TD Cowen to $30, Morgan Stanley to $28, Deutsche Bank to $26, all dated 2026-08-11.
• The only marked insider level in the record is well below the tape: CFO David Wells bought 48,400 shares at $24.23 in the open market, Form 4 dated 2026-05-27.

Bear Case

• The margin reset is the actual event: 64% gross margin versus 76% in Q2 2025, and a swing to an $86.3M net loss from $42.5M of net income. Buying branded GLP-1s instead of dispensing compounded product changes the unit economics of the largest growth line.
• The raise was paid for: FY revenue went up ~$300M at the midpoint while the FY adjusted-EBITDA ceiling came down to $325M from $350M (2026-08-10).
• EPS missed by an order of magnitude: −$0.37 against a −$0.03 consensus, with $28.5M of first-half inventory write-downs and one-time employee compensation inside the first-half result.
• Price sits above most sell-side marks: of the seven targets refreshed after the print, six ($26, $28, $30, $32, $33, $35) sit at or below the 2026-08-21 close of $33.78; only Needham's $42 is above. Barclays cut $39→$35 on 2026-08-21, Citigroup cut to $33 on 2026-08-11.
• The enforcement overhang has no expiry: the FTC action filed 2026-07-29 in the Northern District of California, with state and local co-plaintiffs, alleges pixel trackers shared health information with Meta, Snap and other ad platforms, undisclosed prescription charges, and obstructed cancellation. No hearing or response date has been disclosed. The company restated its rejection of the allegations on 2026-08-19.
• Distribution keeps getting cheaper elsewhere: Amazon Pharmacy at $50/month for eligible Medicare patients (2026-08-06), CVS's program retool (2026-08-05), and Novo Nordisk testing lower-dose Wegovy pills per the WSJ, 2026-08-19 — a lower-dose oral entry point competes directly for the entry-tier weight-loss subscriber.
• Standing dilution reference nearby: the $350M convertible priced in May 2026 converts near $29.53.

Setup & Price Structure

• Last completed daily close $33.78 on 2026-08-21; shares are up 42.2% over three months; RSI(14) at 58.4 is mid-range rather than stretched.
• The pre-print shelf is dated and visible: $31.59 on 2026-08-07, broken to the downside on the 2026-08-10/2026-08-11 sessions, then reclaimed by 2026-08-21. That reclaim is the structure the current leg rests on.
• The $29.53 convertible conversion reference sits under the shelf; the CFO's 2026-05-27 open-market level at $24.23 is the next marked print below that.
• The 52-week high of $62.76 is 46.2% above the last close — this is a recovery leg inside a much larger unwind, not a fresh all-time-high advance.
• Crowding observables: Benzinga whale/unusual-options flags recurred on 2026-08-12 and 2026-08-21, continuing the 2026-06-29 / 2026-07-06 / 2026-07-08 cluster; price trades above six of seven refreshed analyst targets; no earnings date falls inside the next 30 days; the FTC docket carries no scheduled hearing. Insider activity in the record is a purchase, not a sale.
• The narrative is maturing. The catalyst that defined the story came and went on 2026-08-10, the reaccel is now a reported fact rather than a claim, and the 2026-08-11 revision wave was broad but small — five raises landing at $26–$42, most below the tape, plus two cuts on 2026-08-11 and 2026-08-21. Attention is present and flow is moderating; nothing in the last two weeks looks like fresh discovery.

Catalyst Calendar (next 30 days)

• 2026-08-22 → 2026-09-21: no company-scheduled event has been disclosed for this window. The Q2 print (2026-08-10), the call, and the subsequent revision wave (2026-08-11) are all behind. The 30-day window is event-empty on the calendar as published.
• ~2026-11-09 (est.): Q3 2026 results. The $880–900M guide gets marked; the FY $3.1–3.3B revenue and $275–325M adjusted-EBITDA bands get their second test.

Elapsed catalysts

• Undated, ongoing: FTC / state and local action, N.D. Cal., filed 2026-07-29. Any docket entry — motion to dismiss, scheduling order, consent discussions — arrives without notice. (passed 28d ago)
• Undated, ongoing: competitor pricing actions in the GLP-1 lane (Amazon 2026-08-06, CVS 2026-08-05, Novo lower-dose pill testing per WSJ 2026-08-19) have arrived roughly monthly since June and are not on a calendar. (passed 7d ago)

What Would Change Our Mind

The reacceleration question is answered; the open question is whether 64% gross margin is the floor or the first step down. A Q3 report that repeats a double-digit gross-margin decline, or an FY adjusted-EBITDA band cut below $275–325M, would say the branded-GLP-1 shift bought revenue at a permanently worse take rate — that is the datapoint that flips the frame regardless of the top line. Structurally, the leg depends on holding the reclaimed pre-print shelf: a weekly close below $30 puts price back under the $31.59 pre-print reference close and into the $29.53 convertible conversion zone, which would mark the post-print recovery as a failed retest. A litigation reserve or a consent order reaching sign-up and cancellation mechanics would compound it, because those counts go at the machinery that produces recurring revenue. On the other side, a Q3 print above $900M with gross margin stabilizing near 64% would argue the reset was a one-quarter transition cost.

Correlation Notes

• GLP-1 supply chain: now a branded-product reseller in the U.S., so Novo Nordisk and Eli Lilly pricing, dose-tier strategy and channel terms feed directly into gross margin. The WSJ report of Novo testing lower-dose Wegovy pills (2026-08-19) cuts both ways — cheaper entry doses widen the funnel and compress the per-subscriber revenue that just grew 21% YoY.
• Retail-pharmacy and platform entrants: Amazon (2026-08-06) and CVS (2026-08-05) headlines have repriced the whole DTC telehealth complex on announcement days; correlation to those tapes is event-driven rather than continuous.
• High-beta unprofitable-growth cohort: the name appears in Benzinga's daily movers lists alongside Rocket Lab, AST SpaceMobile, Archer Aviation and Plug Power (2026-08-11), and options-flow flags cluster on the same sessions — index-level risk moves show up here amplified.
• Regulatory read-across: the pixel-tracker theory in the 2026-07-29 FTC complaint is being applied across telehealth; adverse developments at peers on the same theory can move this name without a company-specific filing.